- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07279571
GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
AIM 1: Evaluate use of an AI chatbot for HPV vaccine counseling:
PRIMARY OBJECTIVE:
I. To determine patient satisfaction with using an AI chatbot for HPV vaccine counseling.
SECONDARY OBJECTIVE:
I. To understand how patients currently obtain information about cancer care, vaccines, and artificial intelligence.
II. To describe patient experience with the AI-chatbot for vaccine counseling.
AIM 2: Increase rates of HPV vaccine uptake:
PRIMARY OBJECTIVE:
I. To evaluate if implementation of an AI chatbot for HPV vaccine counseling can affect the HPV vaccination rate of new patients served in the gynecologic oncology clinic.
OUTLINE: This is an observational study.
Patients complete a survey on study.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Recruiting
- USC / Norris Comprehensive Cancer Center
-
Principal Investigator:
- Xiaoyue M. Guo
-
Contact:
- Xiaoyue M. Guo
- Phone Number: 323-865-3000
- Email: xiaoyue.guo@med.usc.edu
-
Los Angeles, California, United States, 90033
- Recruiting
- Los Angeles General Medical Center
-
Principal Investigator:
- Xiaoyue M. Guo
-
Contact:
- Xiaoyue M. Guo
- Phone Number: 323-865-3000
- Email: xiaoyue.guo@med.usc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
AI-chatbot Evaluation (Aim 1):
Inclusion Criteria:
- Patient of the LA General gynecologic oncology clinic
- Age 18 years or older
- Previously obtained the HPV vaccination (initial chatbot evaluation)
- Eligible for HPV vaccination (pilot intervention; age <46)
- Willing and able to provide informed consent
Exclusion Criteria:
- Patients who do not speak English or Spanish
- Patients who do not provide informed consent
HPV vaccination rate (Aim 2):
Inclusion Criteria:
- Patient of the LA General gynecologic oncology clinic
- Age 18 years or older
- Obtained the HPV vaccine
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Observational
Patients complete a survey on study.
|
Non-interventional study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Satisfaction Scores
Time Frame: Up to 1 year
|
Patients will complete a survey to assess their satisfaction with using an AI chatbot for HPV vaccine counseling.
|
Up to 1 year
|
|
HPV Vaccination Rate
Time Frame: Up to 1 year
|
HPV vaccination rate for patients who received the HPV vaccine counseling with the AI-chatbot
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Demographics of patients
Time Frame: Up to 1 year
|
Will be analyzed using a qualitative description of the demographics of patients involved in this specific study.
|
Up to 1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Xiaoyue M Guo, University of Southern California
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5U-25-1 (Other Identifier: USC / Norris Comprehensive Cancer Center)
- P30CA014089 (U.S. NIH Grant/Contract)
- NCI-2025-03594 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- UP-25-00331 (Other Identifier: USC IRB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Carcinoma
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnAtypical Endometrial Hyperplasia | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IA Endometrial Carcinoma | Stage IB Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage... and other conditions
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage IVA Endometrial Carcinoma | Stage IVB Endometrial... and other conditionsCanada
-
Case Comprehensive Cancer CenterTerminatedStage IV Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage I Endometrial CarcinomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
National Cancer Institute (NCI)NRG Oncology; Canadian Cancer Trials GroupActive, not recruitingEndometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditionsUnited States, Canada, Puerto Rico, Japan, South Korea
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Endometrial Adenosquamous Cell Carcinoma | Endometrial AdenoacanthomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
Memorial Sloan Kettering Cancer CenterRecruitingEndometrial Cancer | Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage III Endometrial Cancer | Endometrial Carcinoma Stage IIIUnited States
-
National Cancer Institute (NCI)NRG OncologyRecruitingEndometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Endometrial...United States
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.Not yet recruitingRecurrent Endometrial Carcinoma | Advanced Endometrial Carcinoma | Metastatic Endometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial CancerUnited States
Clinical Trials on Non-Interventional Study
-
Ohio State University Comprehensive Cancer CenterCompletedHeavy Metal Exposure From VapingUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingProstate CarcinomaUnited States
-
Mayo ClinicRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterLilly FoundationRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Advanced Breast Carcinoma | Metastatic Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Enrolling by invitationBarrett Esophagus | Esophageal AdenocarcinomaUnited States
-
Portsmouth Hospitals NHS TrustArdia Digital Health LtdNot yet recruitingChronic Kidney Disease
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Glioblastoma | Anatomic Stage IV Breast Cancer AJCC v8 | Lung Carcinoma | Metastatic Breast CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Merck Sharp & Dohme LLCRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Roswell Park Cancer InstituteRecruitingCigarette Smoking-Related CarcinomaUnited States
-
Children's Oncology GroupRecruitingChildhood Hematopoietic and Lymphatic System Neoplasm | Childhood Malignant Solid NeoplasmUnited States